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ABSTRACT
A physician’s recommendation for human papillomavirus (HPV) vaccine is a key predictor of vaccine
uptake; however, little is known about how physicians communicate about HPV vaccine with male
patients. We sought to describe physicians’ HPV vaccine communication practices with males who are of
vaccine-eligible age (9-26 years). We surveyed representative samples of pediatric and family medicine
physicians in Florida, and assessed whether physicians present HPV vaccine as optional or routine, and as
a vaccine that prevents cancer. We also assessed the type of visit during which physicians discuss HPV
vaccine with adolescent males and whether other healthcare providers in the practice discuss HPV vaccine
or make the initial recommendation. We received 367 completed surveys (50.7% response rate). Few
physicians (29.9%) reported they typically present HPV vaccine as routine to males ages 11-12 years, who
constitute the target group for routine vaccination. When discussing HPV vaccination, many physicians
reported somewhat or strongly emphasizing cancer prevention (80.0%). Physicians most often discussed
HPV vaccine when they saw patients for well-child visits (93.0%) and least often at acute care visits
(15.3%). Over half reported that at least one other healthcare professional in their practice discusses
(56.1%) or makes the initial recommendation for (54.9%) HPV vaccination. Many physicians in our sample
are presenting HPV vaccine as optional rather than routine and are missing opportunities to communicate
with males about the vaccine. Our findings identify areas for future interventions to improve physicians’
HPV vaccine communication and, ultimately, increase the use of this cancer-preventing vaccine.
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Introduction
In 2011, the Advisory Committee on Immunization Practices
(ACIP) recommended routine vaccination with quadrivalent
human papillomavirus (HPV) vaccine for males ages 11-
12 years in the United States (US).1 ACIP also recommends
catch-up vaccination for unvaccinated or partially vaccinated
males ages 13-21 years and vaccination up to age 26 for special
populations, including immunocompromised males and men
who have sex with men. Despite these recommendations, HPV
vaccine coverage is low. In 2014, about 42% of males ages 13-
17 in the US had received 1 dose of the three-dose vaccine
series, and only 22% had completed the series.2 Coverage in
Florida is similarly low, which is concerning given that Florida
is among the most populated US states, and has among the
highest rates of HPV-associated anal cancer in males.3 Under-
use of HPV vaccines leaves males vulnerable to unnecessary
and life-threatening HPV-attributable anogenital cancers.4
Many vaccine-eligible adolescents do not receive HPV vac-
cines during visits with healthcare providers during which
another vaccine was administered.5 If these missed
opportunities for HPV vaccination were eliminated, coverage
with 1 dose of HPV vaccine could be as high as 91.3% by age
13 for girls born in the year 2000.5 Some research suggests there
are similar missed opportunities to vaccinate boys against HPV
during preventive care visits.6 To minimize these missed oppor-
tunities, it is critical that providers take advantage of every
healthcare encounter to assess HPV vaccination status7 and
recommend vaccination.
Leaders in public health and medical communities pro-
vide suggestions regarding the content and context of
HPV vaccine recommendation.4,8 With respect to content,
the President’s Cancel Panel recommends that physicians
frame HPV vaccine as a cancer-preventing vaccine,
emphasize vaccine safety and efficacy, and underscore the
importance of vaccinating at age 11 or 12 years.4 With
respect to context, it is clear that opportunities for vacci-
nation extend beyond routine preventive care visits7,8 and
recommendations can be either supported or delivered by
other healthcare team members (e.g., nurses, medical assis-
tants) to introduce, recommend, and/or reinforce HPV
vaccination to patients and parents.9,10
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Research conducted on the content and context of physician
communication about HPV vaccine mostly has examined these
components with female patients only,11,12 without distinguish-
ing patient sex,13,14 or prior to vaccine licensure for males.15,16
We are aware of only two previous studies conducted with
physicians that examined content of their communication with
males after vaccine licensure.17,18 Given that HPV vaccine cov-
erage for males lags behind females and for other adolescent
immunizations,2 understanding these aspects of vaccine com-
munication, particularly in a state with low HPV vaccine
uptake,2 is essential for supporting physicians’ HPV vaccine
recommendations for males. To address this need, we assessed
the content and context of HPV vaccine communication with
male patients and their parents among a statewide sample of
pediatricians and family medicine physicians in Florida.
Results
We randomly selected 770 pediatric and family medicine
physicians based on their proportional representation in
the Florida physician primary care workforce. After receiv-
ing institutional review board approval, we began a six-
wave mailing approach beginning with pre-notice post-
cards mailed in May 2014 and ending with a final
reminder to non-responders in August 2014. We received
367 completed surveys; after accounting for undeliverable
surveys (n D 36) and ineligible respondents (n D 10), the
overall response rate was 50.7%. For our current analyses,
we excluded 12 participants who reported they did not see
male patients ages 9-26, for an analytic sample size of 355.
Sample characteristics
The sample was about equally comprised of female (50.1%) and
male (48.2%) physicians (Table 1). Participants’ average age
was 48.7 years (standard deviation [SD] D 9.0), about 65.6%
were White and 73.0% were non-Hispanic. Half (49.0%) spe-
cialized in family medicine and 49.9% had been practicing for
16 or more years.
Regarding practice characteristics, the highest proportion
(49.0%) of physicians reported their practice had two physi-
cians. About two-thirds (65.6%) described their practice as
single specialty, 64.5% worked in private practice, and
50.7% reported their practice was in a suburban location.
Fewer than half (40.3%) reported seeing mostly White,
non-Hispanic patients, and about 60.6% saw patients who
used either Medicaid or another form of payment. Nearly
half (45.6%) of surveyed physicians were a Vaccines for
Children (VFC) provider.
The anonymous nature of the survey precludes examining
the degree to which survey responders and non-responders
were similar on demographic and practice characteristics.
However, we were able to compare responding physicians to
the population of physicians in Florida meeting our study eligi-
bility criteria on characteristics including age, sex, and clinical
specialty. We found no statistically significant difference in age
for responding physicians (M D 48.7, SD D 9.0) compared to
the larger population of Florida physicians (M D 48.8, SD D
10.0), t(410.67)D 0.28, pD .78. A similar proportion of females
Table 1. Demographic and practice characteristics of physicians who participated in the
survey (ND 355).
Physician characteristics n (%)
Gender
Female 178 (50.1)
Male 171 (48.2)
Missing 6 (1.7)
Age
30-39 64 (18.0)
40-49 124 (34.9)
50 161 (45.4)
Missing 6 (1.7)
Race
White/Caucasian 233 (65.6)
Black/African-American 22 (6.2)
Asian 38 (10.7)
Other 51 (14.4)
Missing 11 (3.1)
Ethnicity
Hispanic 86 (24.2)
Non-Hispanic 259 (73.0)
Missing 10 (2.8)
Years practicing
10 100 (28.2)
11-15 64 (18.0)
16 177 (49.9)
Missing 14 (3.9)
Clinical specialty
Pediatrics 155 (43.7)
Family Medicine 174 (49.0)
Othera 20 (5.6)
Missing 6 (1.7)
Practice characteristics
Number of physicians
1 100 (28.2)
2 174 (49.0)
6-15 46 (13.0)
16 29 (8.2)
Missing 6 (1.7)
Practice situation
Single specialty 233 (65.6)
Multi-specialty 91 (25.6)
Other 25 (7.0)
Missing 6 (1.7)
Practice type
Private practice office 229 (64.5)
Other 112 (31.5)
Missing 14 (3.9)
Practice location
Urban 129 (36.3)
Suburban 180 (50.7)
Rural/Other 33 (9.3)
Missing 13 (3.7)
Race of patients
White, non-Hispanic 143 (40.3)
Minority group(s) 121 (34.1)
No definable majority 67 (18.9)
Missing 24 (6.8)
Medicaid patients
Medicaid only 6 (1.7)
Medicaid and others 215 (60.6)
No Medicaid 97 (27.3)
Missing 37 (10.4)
Typical daily patient volume
<15 41 (11.5)
15-19 96 (27.0)
20-29 155 (43.7)
30 56 (15.8)
Missing 7 (2.0)
VFC provider
Yes 162 (45.6)
No 156 (43.9)
Do not know 35 (9.9)
Missing 2 (0.6)
Notes. Abbreviation: VFC, Vaccines for Children program
a Other clinical specialty includes Urgent Care, Acute Care, Internal Medicine, Hos-
pice, Geriatrics, General Physician, Primary Care, Emergency Room.
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responded to our survey (51.3%) compared to the population of
Florida physicians (46.7%), x2(1, N D 6,907) D 2.82, p D .09.
Survey responders were similar to Florida physicians regarding
pediatric specialty (43.3% responders vs. 37.2% in Florida) and
family medicine specialty (50.3% responders vs. 56.8% in Flor-
ida), x2(2, N D 6,915) D 6.10, p D .05.
Content of HPV vaccine communication
Optional versus routine HPV vaccination
Physicians reported presenting HPV vaccination as routine
most often (35.3%) to males ages 13-17, followed by males ages
18-21 (30.9%) (Fig. 1). Few physicians presented HPV vaccine
as routine to males in the early vaccination group (ages 9-10;
9.1%) and for males in the age group for whom HPV vaccine is
recommended only for special populations (ages 22-26; 22.8%).
Less than one-third (29.9%) reported they typically present
HPV vaccine as routine for 11-12 year old males; an additional
20.9% reported they do not discuss HPV vaccine with this age
group. For all age groups, more physicians reported they pre-
sented HPV vaccine as an optional, rather than routine,
vaccine.
HPV vaccine relative to other adolescent immunizations
Among physicians who did not indicate they do not see 11- to
12-year-old males, more than half (57.3%) recommended HPV
vaccine less strongly and 41.2% recommended HPV vaccine as
strongly as tetanus, diphtheria, and pertussis (Tdap) vaccine
(data not shown). Relative to meningococcal vaccine, about
half (50.9%) recommended HPV vaccine less strongly, whereas
46.2% recommended HPV vaccine as strongly. Few physicians
recommended HPV vaccine more strongly than Tdap (1.5%)
and meningococcal vaccine (2.9%).
Emphasis during discussion
When discussing HPV vaccination with male patients and
their parents, many physicians reported somewhat or
strongly emphasizing cancer prevention (80.0%), sexually
transmitted infection (STI) prevention (77.8%), the impor-
tance of vaccinating prior to the onset of sexual activity
(77.2%), vaccine safety (68.5%), and vaccine efficacy
(64.5%) (Table 2). Over half (57.8%) somewhat or strongly
emphasized all five aspects in their discussions, whereas
13.8% did not emphasize any of the aspects (data not
shown). About three-quarters (76.1%) stressed both STI and
cancer prevention in their discussions, whereas few empha-
sized STI (1.4%) or cancer (3.9%) prevention without
emphasizing the other. Physicians who somewhat or
strongly emphasized cancer prevention tended to emphasize
cervical cancer prevention in female sexual partners
(76.9%); fewer emphasized prevention of anal cancer
(49.8%) and possible prevention of penile cancer (56.0%) in
the patient himself (Table 2).
We further explored whether physicians strongly empha-
sized cancer and STI prevention in their discussions. Regarding
cancer prevention generally, 22.5% of physicians strongly
emphasized prevention of cervical cancer in female sexual part-
ners, prevention of anal cancer in the patient himself, and pos-
sible prevention of penile cancer (data not shown). For STI
prevention, 39.2% of physicians strongly emphasized preven-
tion of genital warts in both the patient himself and in sexual
partners. For the patient himself, about one-third of physicians
strongly emphasized prevention of anal (32.1%) or penile
(31.8%) cancer and just over half (54.6%) strongly emphasized
prevention of genital warts (Table 2).
Context of HPV vaccine communication
Opportunities for communication
Similar numbers of physicians conveyed that they saw ado-
lescent males who presented for school or college physicals
(70.1%), acute care visits (68.2%), well-child visits (68.2%),
and sports physicals (66.2%); fewer saw male patients for
camp physicals (53.2%) and when the patient is in for other
vaccines (42.5%) (Fig. 2). Among those who saw male
patients for a particular type of visit, physicians most often
Figure 1. Physicians’ presentation of HPV vaccine as optional or routine for males, by patient age group. Note. The number of patients seen differs by patient age group:
9–10 years, n D 264; 11–12 years, n D 278; 13–17 years, n D 292; 18–21 years, n D 301; 22–26 years, nD 206.
HUMAN VACCINES & IMMUNOTHERAPEUTICS 1513
also discussed HPV vaccine at well-child visits (93.0%), fol-
lowed by when the patient is in for other vaccines (82.1%),
school or college physicals (81.1%), sports physicals
(56.2%), camp physicals (54.5%), and acute care visits
(15.3%) (data not shown).
Other healthcare professionals
Regarding other healthcare professionals’ involvement in HPV
vaccine discussion and recommendation, over half of physi-
cians indicated that at least one other healthcare professional in
their practice discusses (56.1%) or makes the initial recommen-
dation for (54.9%) HPV vaccination. Physicians most often
reported that a nurse practitioner (30.7%) in their practice dis-
cusses HPV vaccination with patients, followed by a medical
assistant (24.2%), physician assistant (15.8%), and nurse
(14.9%). Similar percentages of physicians reported that these
healthcare professionals make the initial recommendation for
HPV vaccination: nurse practitioner (29.9%), medical assistant
(25.1%), physician assistant (16.6%), and nurse (16.6%).
Discussion
This study describes the content and context of physicians’
communication about HPV vaccine with male patients and
their parents. We found that many primary care physicians in
Table 2. Content of physicians’ discussion about HPV vaccine with male patients and their parents.
Strongly
emphasize
Somewhat
emphasize
Discuss only
if questioned
Do not
discuss
Don’t
know/
not sure
Content area n (%) n (%) n (%) n (%) n (%)
Sexually transmitted infection prevention
Prevention of genital warts in the patient himself 194 (54.6) 76 (21.4) 40 (11.3) 31 (8.7) 4 (1.1)
Prevention of genital warts in sexual partners 146 (41.1) 95 (26.8) 64 (18.0) 37 (10.4) 2 (0.6)
Cancer prevention
Prevention of cervical cancer in female sexual partners 201 (56.6) 72 (20.3) 37 (10.4) 32 (9.0) 2 (0.6)
Prevention of anal cancer in the patient himself 114 (32.1) 63 (17.7) 80 (22.5) 85 (23.9) 4 (1.1)
Possible prevention of penile cancer 113 (31.8) 86 (24.2) 56 (15.8) 85 (23.9) 3 (0.8)
Safety of the vaccine in males 158 (44.5) 85 (23.9) 66 (18.6) 31 (8.7) 5 (1.4)
Efficacy of the vaccine in males 141 (39.7) 88 (24.8) 73 (20.6) 31 (8.7) 9 (2.5)
Importance of vaccination prior to the onset of
sexual activity (for patients who have not initiated sexual activity)
215 (60.6) 59 (16.6) 35 (9.9) 33 (9.3) 4 (1.1)
Note. Percentages account for missing data. Missing data for each item ranged from 9 to 13 participants.
Figure 2. Types of visits at which physicians see male patients and discuss HPV vaccine. Note. 15 participants did not respond to the question regarding the type of visit
where adolescent males are seen. Percentages account for these missing data.
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our sample reported HPV vaccine communication practices
that are inconsistent with national guidelines1 and evidence-
based recommendations.4,8 The Centers for Disease Control
and Prevention suggests that physicians recommend HPV vac-
cine the same way as other adolescent vaccines by stating that
the child needs shots and then listing the ACIP-recommended
vaccines for his or her age.19 Although ACIP recommends rou-
tine vaccination for males ages 11-12,1 only 29.9% present
HPV vaccine as a routine at this age, which is a likely contribu-
tor to low vaccination rates. Although a higher proportion of
physicians reported presenting HPV vaccine as routine for
older ages, far fewer older adolescents present for preventive
care.20 Consequently, a large proportion of these patients may
never receive a routine recommendation, even if it is the physi-
cians’ intent to recommend more strongly at an older age.
In our study, over half of physicians reported recommend-
ing HPV vaccine less strongly than Tdap and meningococcal
vaccines. Our findings echo other research conducted with a
national sample of pediatricians and family physicians.14 This
research found significantly higher proportions of physicians
endorse Tdap (95%) and meningococcal (87%) vaccines com-
pared to HPV vaccine (73%). Moreover, physicians in that
study reported that they perceived parents’ endorsement of
Tdap (74%) and meningococcal (62%) vaccines as much higher
than for HPV vaccine (13%). Thus, physicians may recom-
mend Tdap and meningococcal vaccines more strongly than
HPV vaccine because of their perceived support, and lower
resistance, from parents. Physicians also may be more inclined
to recommend Tdap and meningococcal vaccines more
strongly than HPV vaccine because meningococcal meningitis,
diphtheria, and pertussis are easily transmitted through casual
contact,21-23 whereas HPV is transmitted sexually.
Although not transmitted through casual contact, HPV
infection is common and persistent infection can lead to can-
cer;24 as such, evidence-based approaches to vaccine communi-
cation suggest emphasizing that HPV vaccine prevents cancer.4
In our study, about 80% of physicians somewhat or strongly
emphasized some aspect of the vaccine’s cancer prevention
benefits, but far fewer (22.5%) strongly emphasized cancer pre-
vention for multiple cancers. Moreover, more physicians
highlighted HPV vaccine’s cancer prevention benefits for
female sexual partners than for the male patient himself, with
only about one-third of physicians reporting they strongly
emphasize that HPV vaccine can prevent anal cancer and pos-
sibly prevent penile cancer. This behavior may reflect a limited
understanding of HPV-related disease in and the vaccine’s can-
cer prevention benefits for males.25 Alternatively, one study
found that physicians may be aware of these benefits, but are
uncomfortable discussing anal and penile cancers with male
patients and their parents.17 Some physicians in the study who
acknowledged the cancer prevention benefits for males per-
ceived this benefit as unimportant because of the low incidence
of these cancers and, as a result, do not discuss these cancers
when offering HPV vaccine to males. In our study, more physi-
cians emphasized prevention of genital warts than cancer as a
direct benefit of vaccination. What remains unclear is which
message physicians used to lead their communication and the
depth to which they discuss these messages, and whether these
are important factors in parents’ subsequent agreement to
vaccinate their child. Also, it is important to recognize that
potential variation in physicians’ interpretation of what it
means to somewhat or strongly emphasize cancer or STI pre-
vention limits our understanding of gradations in these discus-
sions. At the same time, available recommendations for vaccine
communication advise physicians in rather general terms, such
as framing HPV vaccine as a vaccine that prevents cancer.4
Additional evidence is needed on what constitutes a strong
emphasis to support best clinical practices and establish a
benchmark for measuring those practices.
Nearly all physicians took advantage of well-child visits to
discuss HPV vaccine, but are missing other opportunities to
communicate with males about the vaccine, particularly sick
visits. This finding is consistent with previous research indicat-
ing that fewer than half of physicians discuss adolescent vac-
cines at sick visits; however, when they do, physicians more
often discuss Tdap and meningococcal vaccine than HPV vac-
cine.14 Physicians who reported not discussing adolescent vac-
cines during sick visits most often cited that vaccination is
better suited for a well visit. Physicians’ disinclination to discuss
HPV vaccine outside of well-child visits is particularly worri-
some because boys’ compliance with well-child visit recom-
mendations declines after age 1226 and teenage boys usually
visit a healthcare provider as a result of acute illness or injury.27
Thus, not taking advantage of every clinical encounter to dis-
cuss HPV vaccine perpetuates the current problem of missing
opportunities for vaccination and undermining HPV-related
cancer prevention efforts.
Over half of physicians in our study indicated that other
healthcare providers in their practice setting discuss and rec-
ommend HPV vaccine. Given documented barriers related to
physicians’ time to discuss HPV vaccination,28,29 non-physician
healthcare providers can be instrumental in facilitating vaccine
uptake. These professionals may have more frequent and
extended contact with patients,30 allowing greater opportunity
to discuss and recommend HPV vaccination. We are aware of
few studies that have targeted this group directly as a means to
reduce missed clinical opportunities for HPV vaccination. One
intervention study found that a structured presentation was
effective in increasing physicians’ and non-physician healthcare
workers’ knowledge about HPV vaccine.31 Although these
results are promising, we recognize that changes in knowledge
do not necessarily translate to changes in clinical practice
behaviors. Additional research is needed on non-physician
healthcare providers’ role in and needs for effectively commu-
nicating about HPV vaccination.
To our knowledge, our study is among the first to focus on
both the content and context of physicians’ HPV vaccine com-
munication specifically with male adolescent patients and their
parents. Study strengths include a statewide sample of primary
care providers in Florida and an examination of multiple com-
ponents of physicians’ communication.
Although assessing physicians’ perspectives is a study
strength, the self-reported survey data we collected also are a
limitation given that physicians may have reported socially
desirable behaviors or their responses may have been subject to
recall bias. Second, our survey response rate was 50.7%; thus,
our findings may be subject to nonresponse bias, thereby limit-
ing the generalizability of our results. Third, the cross-sectional
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study design precludes our ability to examine whether physi-
cian communication about HPV vaccine results in subsequent
vaccine uptake. Fourth, the survey design did not allow us to
differentiate communication content and context based on the
adolescent’s age. Because some research shows that physicians’
communication is influenced by patient age,17 future research
should further examine this relationship. Also, the survey did
not assess physicians’ discussion of oropharyngeal cancer pre-
vention. Although HPV vaccine is not indicated for prevention
of oropharyngeal cancers,32 about 72% of oropharyngeal can-
cers are probably caused by HPV.33 Thus, some physicians may
emphasize possible prevention of oropharyngeal cancers in
their discussions. Finally, our survey did not include quantita-
tive anchors to help standardize the distinction between
strongly emphasize and somewhat emphasize responses; thus,
physicians’ interpretation of these response options may vary.
Taken together, our findings identify areas for future inter-
ventions to improve physicians’ HPV vaccine communication
and, ultimately, increase the use of this cancer-preventing vac-
cine. These areas include helping physicians present HPV vac-
cine as a routine part of the adolescent vaccination platform at
ages 11-12 when males are still presenting routinely for well-
child care, and as a vaccine that prevents cancer; to take advan-
tage of all clinical encounters, particularly acute visits; and to
maximize the use of support offered by non-physician health-
care professionals in communicating about HPV vaccination
with patients. Without such interventions to support physi-
cians’ communication, HPV vaccine may remain underused by
males, leaving them susceptible to unnecessary and preventable
cancers.
Methods
Recruitment
We obtained a full mailing list of Florida-based pediatricians
and family medicine physicians from an American Medical
Association (AMA) Physician Masterfile licensee. Exclusion
criteria were: 1) trainee status (i.e., residents and fellows), 2)
locum tenens, 3) non-patient care reported as their major pro-
fessional activity, 4) age 65 years or older, given that the AMA
Masterfile has shown a significant lag in posting physician
retirements,34 and 5) post office box listed as an address, which
would preclude our ability to reach physicians using our FedEx
mailing strategy. We randomly selected physicians from pediat-
ric and family medicine specialties based on their proportional
representation in the Florida physician primary care workforce
(n D 770). After receiving institutional review board approval,
we mailed pre-notice postcards in May 2014. We mailed the
first wave of surveys via FedEx in June 2014 and sent reminders
to non-responders through August 2014. The first survey
packet included an up-front $25 cash incentive to participate.
Instrument
Our anonymous survey assessed multiple components of the
content of physicians’ communication about HPV vaccine and
the context in which it occurs. Survey items pertaining to con-
tent and context were based in part on a previous survey on
physician recommendation for HPV vaccination of males.35 To
be clear, we asked physicians to respond to all items with regard
to their male patients. We assessed the content of physicians’
discussions about HPV vaccine for three domains. First, the
survey asked physicians, “How do you usually present the HPV
vaccine to your male patients/parents of male patients, in the
following age groups [9-10, 11-12, 13-17, 18-21, 22-26]?”
Response options included HPV vaccine is optional, HPV vac-
cine is routine, I do not discuss HPV vaccine with this age group,
and I do not see male patients in this age group. Second, because
ACIP guidelines recommend routine HPV vaccination for
11-12 year old males,36 we asked physicians two questions
regarding the strength with which they recommend HPV vac-
cine relative to other ACIP-recommended vaccines on the
11-12 year old immunization platform. The survey asked, “For
11-12-year-old males, I recommend the HPV vaccine [less
strongly than MCV4/Tdap, as strongly as MCV4/Tdap, more
strongly than MCV4/Tdap].” MCV4 refers to meningococcal
conjugate vaccine and Tdap refers to tetanus, diphtheria, and
pertussis vaccine. Physicians also could indicate they do not see
11- to 12-year-old males.
Third, we assessed the content of physicians’ discussions by
asking, “When discussing HPV vaccination with male patients
and their parents, how much emphasis do you place on the fol-
lowing aspects of the vaccine?” Content areas included preven-
tion of genital warts in the patient himself, prevention of
genital warts in sexual partners, prevention of cervical cancer
in female sexual partners, prevention of anal cancer in the
patient himself, possible prevention of penile cancer, vaccine
safety in males, vaccine efficacy in males, and importance of
vaccination prior to the onset of sexual activity (for patients
who have not initiated sexual activity). Response options
included strongly emphasize, somewhat emphasize, discuss only
if questioned, do not discuss, and don’t know/not sure. We
reviewed these items individually, as well as examined emphasis
on prevention of STIs and cancer on a broader scale. The two
items pertaining to genital warts were collapsed to reflect dis-
cussion about STI prevention such that a somewhat emphasize
or strongly emphasize response to at least one item constituted
a discussion about STI prevention. The three items pertaining
to cancer were similarly collapsed to reflect discussion about
cancer prevention.
Context of physicians’ HPV vaccine communication was
assessed by asking two separate questions about the types of
visits where physicians (1) see and (2) discuss HPV vaccination
with adolescent males. The survey asked, “During what type of
visit do you usually [see adolescent males, discuss HPV vacci-
nation with adolescent males]?” Visit types included acute care
visits, well-child visits, when the patient is in for other vaccines,
school or college physicals, sports physicals, camp physicals, or
other. We used these two items to create a variable that allowed
us to examine whether physicians discuss HPV vaccine during
the type(s) of visit(s) at which they see adolescent males. We
also assessed context by asking two questions about other
healthcare professionals’ involvement in HPV vaccine recom-
mendation and discussion: “In addition to you, do any of the
following other healthcare professionals in your practice setting
[make the initial recommendation for, discuss] HPV vaccina-
tion?” Response options included medical assistant, nurse (RN
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or BSN), nurse practitioner, physician assistant, other, or none of
the above.
Physician characteristics measured included sex, age, race,
ethnicity, number of years in practice, and clinical specialty.
Practice characteristics included the number of physicians in
the practice, practice situation (single specialty, multispecialty,
other), practice type (private, other), practice location (urban,
suburban, rural, other), race/ethnic category of the majority of
patients seen, whether the practice serves patients who use
Medicaid (Medicaid patients only, Medicaid and privately
insured patients, no Medicaid patients), typical daily patient
load, and whether the physician is a VFC provider.
Data analysis
We calculated frequencies and percentages for all variables
using the SAS 9.3 statistical software package (SAS Institute
Inc., Cary, North Carolina).
Abbreviations
ACIP Advisory Committee on Immunization Practices
AMA American Medical Association
HPV human papillomavirus
MCV4 meningococcal conjugate vaccine
STI sexually transmitted infection
Tdap tetanus, diphtheria, pertussis
VFC Vaccines for Children program
US United States
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